Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031564 | 0.89 | RAB9A (0.60) | RAB9AMAPTKDM4EALDH1A1CYP2D6 | |
| SCHEMBL8297049 | 0.87 | RAB9A (0.59) | RAB9AMAPTKDM4EALDH1A1CYP2D6 | |
| SCHEMBL20614246 | 0.86 | RAB9A (0.57) | RAB9AMAPTKDM4EALDH1A1CYP2D6 | |
| SCHEMBL15649780 | 0.84 | RAB9A (0.56) | RAB9AMAPTKDM4EALDH1A1CYP2D6 | |
| SCHEMBL10751886 | 0.84 | RAB9A (0.53) | RAB9AMAPTKDM4EALDH1A1CYP2D6 | |
| SCHEMBL13000171 | 0.83 | TUBB4A (0.47) | RAB9AMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10729232 | 0.83 | RAB9A (0.55) | RAB9AMAPTKDM4EALDH1A1CYP2D6 | |
| SCHEMBL11158875 | 0.83 | RAB9A (0.55) | RAB9AMAPTKDM4EALDH1A1CYP2D6 | |
| SCHEMBL12777065 | 0.82 | SMN1; SMN2 (0.45) | RAB9AMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10729189 | 0.82 | GABRA1 (0.65) | RAB9AMAPTKDM4EALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408789-A1 | DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES | Centre National De La Recherche Scientifique CNRS (FR) | 2012-01-25 | — | — | EP | disclosed |
| US-20120016155-A1 | DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-01-19 | — | — | US | disclosed |
| WO-2010106526-A1 | DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016155-A1 | DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES | PTH1R, P4HA1, FGF23 | RAB9A 1883/4885MAPT 4645/4885KDM4E 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.